Ordering RecommendationRecommendations when to order or not order the test. May include related or preferred tests.
Optimize drug therapy and monitor patient adherence.
MnemonicUnique test identifier.
PRAZE
MethodologyProcess(es) used to perform the test.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
PerformedDays of the week the test is performed.
Tue, Fri
ReportedExpected turnaround time for a result, beginning when ARUP has received the specimen.
1-5 days
New York DOH Approval StatusIndicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Specimen Required
Patient Preparation
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Collect
Gray (Potassium Oxalate/Sodium Fluoride). Also acceptable: Plain Red, Green (Sodium Heparin), Lavender (K2 or K3EDTA) or pink (K2EDTA).
Specimen Preparation
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1 mL)
Storage/Transport Temperature
Refrigerated.
Unacceptable Conditions
Gel separator tubes. Plasma or whole blood collected in light blue (sodium citrate). Hemolyzed specimens.
Remarks
Stability
After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years (Avoid repeated freeze/thaw cycles)
Reference IntervalNormal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Effective November 16, 2015
Dose-Related Range:
Prazepam (Dose: 20-60 mg/d) (Assayed as Nordiazepam)
Nordiazepam:
100-1500 ng/mL
Toxic:
Greater than 2500 ng/mL
Interpretive DataBackground information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
Prazepam is not detected in serum due to its rapid metabolism to nordiazepam. Adverse effects may include dizziness, fatigue, drowsiness, ataxia and weakness.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Compliance Category
Laboratory Developed Test (LDT)
NoteAdditional information related to the test.
Hotline History
N/A
CPT CodesThe American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
AliasesOther names that describe the test. Synonyms.
Chat
Feedback
